Drug Development Pipeline
Brensocatib is an oral drug designed to block the function of enzymes, such as neutrophil elastase, that play an essential role in inflammation. When the lungs are infected with bacteria, white blood cells release these enzymes, including neutrophil elastase, to fight the infection. In CF, these enzymes can result in excessive inflammation that causes damage to the lungs. Brensocatib may decrease this damage by inhibiting neutrophil elastase and decreasing inflammation in the lungs.
A Phase 2 study to test the safety of brensocatib in adults with CF is underway.
This program is sponsored by Insmed. It is being conducted within the Therapeutics Development Network (TDN).
Recent Brensocatib Studies
Closed to Enrollment
Sign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Explore clinical trials
Be a part of the movement transforming the future of cystic fibrosis treatment.Learn More